Last reviewed · How we verify
Dehydrated human amnion/chorion membrane
Dehydrated human amnion/chorion membrane provides a biologic scaffold that promotes wound healing and tissue regeneration through delivery of growth factors and extracellular matrix components.
Dehydrated human amnion/chorion membrane provides a biologic scaffold that promotes wound healing and tissue regeneration through delivery of growth factors and extracellular matrix components. Used for Chronic wounds (diabetic foot ulcers, venous leg ulcers), Acute wounds and surgical sites, Burn wounds.
At a glance
| Generic name | Dehydrated human amnion/chorion membrane |
|---|---|
| Also known as | EpiFix, dHACM |
| Sponsor | Louisiana State University Health Sciences Center in New Orleans |
| Drug class | Biologic allograft / Regenerative tissue product |
| Modality | Biologic |
| Therapeutic area | Wound Care / Regenerative Medicine |
| Phase | FDA-approved |
Mechanism of action
This allograft tissue product is derived from human placental membranes and contains native growth factors, cytokines, and extracellular matrix proteins that support tissue repair and reduce inflammation. When applied to wounds or tissue defects, it acts as a biological dressing and regenerative scaffold, facilitating epithelialization and tissue remodeling while providing antimicrobial and anti-inflammatory properties.
Approved indications
- Chronic wounds (diabetic foot ulcers, venous leg ulcers)
- Acute wounds and surgical sites
- Burn wounds
- Ophthalmic surface reconstruction
Common side effects
- Infection at application site
- Allergic reaction / sensitization
- Delayed wound healing
- Graft rejection
Key clinical trials
- A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers (NA)
- Evaluation of the Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft vs Standard of Care in the Treatment of Partial Thickness Thermal Burns (PHASE4)
- Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers (NA)
- Evaluating the Efficacy of NeoThelium FT in the Treatment of Chronic Open Wounds (NA)
- Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Diabetic Foot Ulcers (NA)
- Evaluation of the Safety and Efficacy of Dehydrated Human Placenta Tissue (dHPT) for Wound Healing
- Regenerative Outcomes for Peri-implant Bony Defects Using Amnion-chorion Barrier vs. Collagen Membrane (NA)
- Evaluating the Efficacy of NeoThelium FT in the Treatment of Venous Leg Ulcers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: